Recent Updates
Recently added Catalysts
PRLD Positive Sentiment

PRT543, a protein arginine methyltransferase 5 inhibitor, in patients with advanced adenoid cystic carcinoma: An open-label, phase I dose-expansion study

Monday, December 25, 2023 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: The article discusses a phase I dose-expansion study of PRT543, a protein arginine methyltransferase 5 inhibitor, in patients with advanced adenoid cystic carcinoma. The study aims to evaluate the safety and efficacy of this novel treatment. The involvement of a diverse group of researchers highlights the collaborative effort in advancing cancer therapies.
Price reaction · baseline $4.21 (2023-12-22 close) · clean, no other PRLD news in the window
day 0 close
-0.7%

Market Sentiment Analysis

POSITIVE FACTORS

  • The study focuses on a novel treatment for advanced adenoid cystic carcinoma.
  • PRT543 shows promise as a protein arginine methyltransferase 5 inhibitor.
  • The open-label design allows for real-world applicability of results.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+217%
120-day peak, hindsight
Typical move
8.2%
average across 4 past catalysts
Cash runway
~29 mo
Minimal dilution risk
Lead asset
PRT1419
Phase 1 · Multiple Myeloma

Full Press Release Details

Renata Ferrarotto, Paul L. Swiecicki, Dan P. Zandberg, Robert A. Baiocchi, Robert Wesolowski, Cristina P. Rodriguez, Meredith McKean, Hyunseok Kang, Varun Monga, Rajneesh Nath, Neil Palmisiano, Naveen Babbar, William Sun, Glenn J. Hanna
DOI: 10.1016/j.oraloncology.2023.106634

Frequently Asked Questions

What is PRT543?

PRT543 is a protein arginine methyltransferase 5 inhibitor being studied for cancer treatment.

What type of cancer is being targeted in the study?

The study targets advanced adenoid cystic carcinoma.

What phase is the PRT543 study currently in?

The study is currently in phase I dose-expansion.

Who are the researchers involved in the study?

The study involves a diverse group of researchers including Renata Ferrarotto and Paul L. Swiecicki.

ShareAdd on Google
Tags: PRLD Viatris Investor Conferences Healthcare PRT543 adenoid cystic carcinoma protein arginine methyltransferase 5 phase I study cancer therapy
Last updated: Dec 25, 2023

Biotech snapshot

Cash runway
$152M liquidity · $5M/mo burn
~29 mo
Minimal dilution risk
Lead asset
PRT1419Phase 1
Multiple Myeloma →

Catalyst track record

+217%
best trade around PRLD's most recent catalyst

Peak hindsight return over a 120-day window, across 4 tracked FDA/PDUFA catalysts for PRLD.

See every catalyst's timing & PoA →